Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 322

1.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazières J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 May 24. pii: mdz167. doi: 10.1093/annonc/mdz167. [Epub ahead of print]

PMID:
31125062
2.

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival.

Suidan AM, Roisman L, Belilovski Rozenblum A, Ilouze M, Dudnik E, Zer A, Peled N.

J Glob Oncol. 2019 May;5:1-8. doi: 10.1200/JGO.18.00216. No abstract available.

3.

Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.

Dudnik E, Bar J, Peled N, Bshara E, Kuznetsov T, Cohen AY, Shochat T, Nechushtan H, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadar N, Urban D, Mishaeli M, Rabinovich NM, Brenner R, Zer A, Rotem O, Roisman LC, Wollner M; Israel Lung Cancer Group.

Clin Lung Cancer. 2019 Apr 5. pii: S1525-7304(19)30080-4. doi: 10.1016/j.cllc.2019.03.007. [Epub ahead of print]

PMID:
31060855
4.

Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.

Bedas A, Peled N, Maimon Rabinovich N, Mishaeli M, Shochat T, Zer A, Rotem O, Allen AM, Bar J, Dudnik E; On behalf of the Israel Lung Cancer Group.

Oncol Res Treat. 2019;42(5):275-282. doi: 10.1159/000499086. Epub 2019 Apr 5.

PMID:
30955009
5.

Consistent linear and non-linear responses to invasive electrical brain stimulation across individuals and primate species with implanted electrodes.

Basu I, Robertson MM, Crocker B, Peled N, Farnes K, Vallejo-Lopez DI, Deng H, Thombs M, Martinez-Rubio C, Cheng JJ, McDonald E, Dougherty DD, Eskandar EN, Widge AS, Paulk AC, Cash SS.

Brain Stimul. 2019 Mar 11. pii: S1935-861X(19)30086-5. doi: 10.1016/j.brs.2019.03.007. [Epub ahead of print]

6.

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma.

Rouvinov K, Nalbandyan K, Kozlov V, Peled N, Yakobson A.

Case Rep Oncol. 2019 Jan 4;12(1):29-32. doi: 10.1159/000495980. eCollection 2019 Jan-Apr.

7.

Correction to: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity.

Aravot D, Barac YD, Krutzwald-Josefson E, Allen AM, Flex D, Peled N, Kramer MR, Peysakhovich Y, Saute M.

J Cardiothorac Surg. 2019 Feb 12;14(1):37. doi: 10.1186/s13019-019-0856-4.

8.

Two are better than one on progression through MET mechanism for EGFR+ NSCLC patients.

Kian W, Roisman LC, Peled N.

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S334-S335. doi: 10.21037/tlcr.2018.12.01. No abstract available.

9.

Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity.

Aravot D, Barac YD, Krutzwald-Josefson E, Allen AM, Flex D, Peled N, Kramer MR, Peysakhovich Y, Saute M.

J Cardiothorac Surg. 2019 Jan 9;14(1):7. doi: 10.1186/s13019-018-0829-z. Erratum in: J Cardiothorac Surg. 2019 Feb 12;14(1):37.

10.

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR.

J Clin Oncol. 2019 Mar 1;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8.

PMID:
30620668
11.

Cortical Signal Suppression (CSS) for Detection of Subcortical Activity Using MEG and EEG.

Samuelsson JG, Khan S, Sundaram P, Peled N, Hämäläinen MS.

Brain Topogr. 2019 Mar;32(2):215-228. doi: 10.1007/s10548-018-00694-5. Epub 2019 Jan 3.

PMID:
30604048
12.

Lumbar Schmorl's Nodes and Their Correlation with Spine Configuration and Degeneration.

Abbas J, Hamoud K, Peled N, Hershkovitz I.

Biomed Res Int. 2018 Nov 7;2018:1574020. doi: 10.1155/2018/1574020. eCollection 2018.

13.

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.

Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, Mazzone PJ, Montuenga LM.

J Thorac Oncol. 2019 Mar;14(3):343-357. doi: 10.1016/j.jtho.2018.11.023. Epub 2018 Dec 4. Review.

PMID:
30529598
14.

Increased Risk for Cancer in Young Patients with Severe Obstructive Sleep Apnea.

Brenner R, Kivity S, Peker M, Reinhorn D, Keinan-Boker L, Silverman B, Liphsitz I, Kolitz T, Levy C, Shlomi D, Pillar G, Peled N.

Respiration. 2019;97(1):15-23. doi: 10.1159/000486577. Epub 2018 Nov 12.

PMID:
30419556
15.

Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.

Lam VK, Tran HT, Banks KC, Lanman RB, Rinsurongkawong W, Peled N, Lewis J, Lee JJ, Roth J, Roarty EB, Swisher S, Talasaz A, Futreal PA, Papadimitrakopoulou V, Heymach JV, Zhang J.

Clin Lung Cancer. 2019 Jan;20(1):30-36.e3. doi: 10.1016/j.cllc.2018.08.020. Epub 2018 Sep 5.

16.

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).

Dudnik E, Bshara E, Grubstein A, Fridel L, Shochat T, Roisman LC, Ilouze M, Rozenblum AB, Geva S, Zer A, Rotem O, Allen AM, Peled N.

Lung Cancer. 2018 Oct;124:117-124. doi: 10.1016/j.lungcan.2018.07.044. Epub 2018 Aug 3.

PMID:
30268448
17.

ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?

Cabillic F, Hofman P, Ilie M, Peled N, Hochmair M, Dietel M, Von Laffert M, Gosney JR, Lopez-Rios F, Erb G, Schalles U, Barlesi F.

ESMO Open. 2018 Sep 17;3(6):e000419. doi: 10.1136/esmoopen-2018-000419. eCollection 2018.

18.

Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma.

Simon M, Shochat T, Peled N, Zer A, Kramer MR, Eldan O, Saute M, Dudnik ER, Allen AM.

Thorac Cancer. 2018 Nov;9(11):1470-1475. doi: 10.1111/1759-7714.12860. Epub 2018 Sep 21.

19.

New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey.

Berghmans T, Evison M, Blum TG, Peled N, Cadranel J.

ERJ Open Res. 2018 Sep 3;4(3). pii: 00040-2018. doi: 10.1183/23120541.00040-2018. eCollection 2018 Jul.

20.

The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.

Laufer-Geva S, Rozenblum AB, Twito T, Grinberg R, Dvir A, Soussan-Gutman L, Ilouze M, Roisman LC, Dudnik E, Zer A, Rotem O, Lanman RB, Peled N.

J Thorac Oncol. 2018 Nov;13(11):1705-1716. doi: 10.1016/j.jtho.2018.07.101. Epub 2018 Aug 16.

PMID:
30121392
21.

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O.

J Thorac Oncol. 2018 Oct;13(10):1595-1601. doi: 10.1016/j.jtho.2018.07.004. Epub 2018 Jul 11.

PMID:
30017832
22.

Non-invasive early detection of malignant pulmonary nodules by FISH-based sputum test.

Shlomi D, Peled N, Schwarz YA, Soo Hoo GW, Batra RK, Fink G, Kaplan T, Cohen L, Mollan S, Burfeind WR Jr.

Cancer Genet. 2018 Oct;226-227:1-10. doi: 10.1016/j.cancergen.2018.04.118. Epub 2018 May 10.

PMID:
30005848
23.

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.

Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN Jr, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB.

J Thorac Oncol. 2018 Oct;13(10):1560-1568. doi: 10.1016/j.jtho.2018.06.019. Epub 2018 Jul 5.

PMID:
29981927
24.

Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009-June 20151.

Regev-Yochay G, Reisenberg K, Katzir M, Wiener-Well Y, Rahav G, Strahilevitz J, Istomin V, Tsyba E, Peretz A, Khakshoor S, Dagan R; Israeli Adult Invasive Pneumococcal Disease Group.

Emerg Infect Dis. 2018 Jul;24(7):1275-1284. doi: 10.3201/eid2407.170721.

25.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

PMID:
29885479
26.

Assembly 11: thoracic oncology.

Bostantzoglou C, Peled N.

Breathe (Sheff). 2018 Jun;14(2):163-164. doi: 10.1183/20734735.016918.

27.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

PMID:
29773717
28.

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.

Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadari N, Urban D, Mishaeli M, Zer A, Allen AM, Rabinovich NM, Rotem O, Kuznetsov T, Shochat T, Roisman LC, Bar J; Israel Lung Cancer Group.

J Thorac Oncol. 2018 Aug;13(8):1128-1137. doi: 10.1016/j.jtho.2018.04.024. Epub 2018 Apr 30.

PMID:
29723688
29.

Stereotactic body radiotherapy for central lung tumors, yes we can!

Korzets Ceder Y, Fenig E, Popvtzer A, Peled N, Kramer MR, Saute M, Bragilovsky D, Schochat T, Allen AM.

Radiat Oncol. 2018 Apr 25;13(1):77. doi: 10.1186/s13014-018-1017-y.

30.

High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer.

Allen AM, Shochat T, Flex D, Kramer MR, Zer A, Peled N, Dudnik E, Fenig E, Saute M.

Oncology. 2018;95(1):13-19. doi: 10.1159/000487928. Epub 2018 Apr 20.

PMID:
29680834
31.

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators.

N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.

32.

Reply.

Brenner R, Ben-Zvi I, Shinar Y, Livneh A, Liphshitz I, Silverman B, Peled N, Levy C, Ben-Chetrit E, Kivity S.

Arthritis Rheumatol. 2018 Jul;70(7):1167-1168. doi: 10.1002/art.40496. Epub 2018 May 14. No abstract available.

PMID:
29569855
33.

The earliest modern humans outside Africa.

Hershkovitz I, Weber GW, Quam R, Duval M, Grün R, Kinsley L, Ayalon A, Bar-Matthews M, Valladas H, Mercier N, Arsuaga JL, Martinón-Torres M, Bermúdez de Castro JM, Fornai C, Martín-Francés L, Sarig R, May H, Krenn VA, Slon V, Rodríguez L, García R, Lorenzo C, Carretero JM, Frumkin A, Shahack-Gross R, Bar-Yosef Mayer DE, Cui Y, Wu X, Peled N, Groman-Yaroslavski I, Weissbrod L, Yeshurun R, Tsatskin A, Zaidner Y, Weinstein-Evron M.

Science. 2018 Jan 26;359(6374):456-459. doi: 10.1126/science.aap8369.

PMID:
29371468
34.

A molecular signature of lung cancer: potential biomarkers for adenocarcinoma and squamous cell carcinoma.

Shoshan-Barmatz V, Bishitz Y, Paul A, Krelin Y, Nakdimon I, Peled N, Lavon A, Rudoy-Zilberman E, Refaely Y.

Oncotarget. 2017 Nov 6;8(62):105492-105509. doi: 10.18632/oncotarget.22298. eCollection 2017 Dec 1.

35.

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.

Dudnik E, Moskovitz M, Daher S, Shamai S, Hanovich E, Grubstein A, Shochat T, Wollner M, Bar J, Merimsky O, Zer A, Goldstein DA, Hammerman A, Cyjon A, Shechtman Y, Abu-Amna M, Flex D, Roisman LC, Peled N; Israel Lung Cancer Group.

Lung Cancer. 2018 Dec;126:217-223. doi: 10.1016/j.lungcan.2017.11.015. Epub 2017 Nov 23.

PMID:
29254746
36.

Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion.

Landman Y, Ilouze M, Wein S, Neiman V, Yerushalmi R, Yakimov M, Ku N, Schrock AB, Ali S, Peled N.

Clin Breast Cancer. 2018 Jun;18(3):e267-e270. doi: 10.1016/j.clbc.2017.11.017. Epub 2017 Nov 28. No abstract available.

PMID:
29233640
37.

[THE IMPACT OF MOLECULAR PROFILING USING NEXT-GENERATION SEQUENCING IN ADVANCED LUNG CANCER].

Belilovski Rozenblum A, Ilouze M, Dudnik E, Soussan-Gutman L, Dvir A, Peled N.

Harefuah. 2017 Nov;156(11):686-691. Hebrew.

PMID:
29198084
38.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators.

N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.

39.

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.

Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M.

Lancet Oncol. 2017 Dec;18(12):1600-1609. doi: 10.1016/S1470-2045(17)30690-3. Epub 2017 Nov 9.

PMID:
29129441
40.

Familial Mediterranean Fever and Incidence of Cancer: An Analysis of 8,534 Israeli Patients With 258,803 Person-Years.

Brenner R, Ben-Zvi I, Shinar Y, Liphshitz I, Silverman B, Peled N, Levy C, Ben-Chetrit E, Livneh A, Kivity S.

Arthritis Rheumatol. 2018 Jan;70(1):127-133. doi: 10.1002/art.40344. Epub 2017 Dec 7.

41.

Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.

Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W, Maki R, Gaya A, Bedi A, Zacharoulis S, Ravi R, Wexler LH, Hoque MO, Rodriguez-Galindo C, Pass H, Peled N, Davies A, Morris R, Hidalgo M, Sidransky D.

Ann Oncol. 2017 Oct 1;28(10):2595-2605. doi: 10.1093/annonc/mdx416.

42.

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG.

Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1.

43.

Determination of asthma control using administrative data regarding short-acting beta-agonist inhaler purchase.

Shlomi D, Katz I, Segel MJ, Oberman B, Peled N.

J Asthma. 2018 May;55(5):571-577. doi: 10.1080/02770903.2017.1348513. Epub 2017 Aug 16.

PMID:
28759272
44.

Detection of Lung Cancer and EGFR Mutation by Electronic Nose System.

Shlomi D, Abud M, Liran O, Bar J, Gai-Mor N, Ilouze M, Onn A, Ben-Nun A, Haick H, Peled N.

J Thorac Oncol. 2017 Oct;12(10):1544-1551. doi: 10.1016/j.jtho.2017.06.073. Epub 2017 Jul 12.

45.

Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects.

Nardi-Agmon I, Peled N.

Lung Cancer (Auckl). 2017 May 17;8:31-38. doi: 10.2147/LCTT.S104205. eCollection 2017. Review.

46.

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.

Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA.

Cancer Res. 2017 Aug 15;77(16):4498-4505. doi: 10.1158/0008-5472.CAN-16-1944. Epub 2017 May 18.

47.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

48.

In the quest for degenerative lumbar spinal stenosis etiology: the Schmorl's nodes model.

Abbas J, Slon V, Stein D, Peled N, Hershkovitz I, Hamoud K.

BMC Musculoskelet Disord. 2017 Apr 20;18(1):164. doi: 10.1186/s12891-017-1512-6.

49.

Coherence and content of relating emotions to life events in autism spectrum disorder and typical development: a cross-sectional age study.

Ben-Itzchak E, Kirzon M, Peled N, Zachor DA.

J Abnorm Child Psychol. 2018 Feb;46(2):415-422. doi: 10.1007/s10802-017-0302-9.

PMID:
28401440
50.

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.

Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ.

J Thorac Oncol. 2017 Jun;12(6):932-942. doi: 10.1016/j.jtho.2017.03.005. Epub 2017 Mar 16.

Supplemental Content

Loading ...
Support Center